Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubuntu Phase 3 mRNA COVID-19 vaccine efficacy study in adults at risk of severe COVID-19
PACTR202105817814362Phase 3Completed
- Sponsor
- South African Medical Research Council
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 7
01
Overview
Phase 3, randomised trial of elasomeran and elasomeran + davesomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by South African Medical Research Council. Primary endpoints: Relative risk of symptomatic COVID-19 in pre-Month 6 stage, Relative risk of severe COVID-19 in pre-Month 6 stage and 3 more. Started Jun 2021; status: completed.
02
Drugs
elasomeranelasomeran + davesomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202105817814362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202105817814362.